Novartis entered a licensing agreement with Xencor potentially worth more than $2.5 billion for the development of bispecific antibodies for treating cancer, the companies said Tuesday. The deal includes a $150 million upfront payment to Xencor, with the company also eligible to receive more than $2.4 billion in clinical, regulatory and sales milestone payments if all programmes are successful.
"This collaboration is part of our strategy to join forces with technology innovators who can help us rapidly advance new medicines to the clinic," commented Jay Bradner, president of the Novartis Institutes for BioMedical Research, adding "we look forward to working with the Xencor team to advance these programs in immuno-oncology and to using their antibody engineering platform to develop biotherapeutics for additional diseases."
Under the agreed terms, the companies will jointly develop Xencor's experimental bispecific T-cell engaging antibodies XmAb14045 for acute myeloid leukaemia and XmAb13676 for B-cell malignancies, with both investigational therapies expected to begin clinical development this year. The drugmakers will share development costs for the drugs, which target the CD3 domain, with Novartis receiving commercialisation rights in all markets outside the US.
Additionally, Novartis will be granted rights to four bispecific antibodies, one of which Xencor could elect to co-develop in the US. The Swiss drugmaker will also hold a global non-exclusive option to use Xencor's XmAb Fc technologies for as many as 10 additional biotherapeutic programmes across the company's portfolio.
The companies noted that Xencor will be eligible for tiered, low double-digit royalties on sales of XmAb14045 and XmAb13676 outside the US and mid-single-digit tiered royalties for global sales of the four proprietary bispecific antibodies, unless the drugmaker exercises its option to co-develop one of the molecules and share developmental costs and US profits. Xencor will also receive low single-digit royalties on any Novartis molecules utilising its XmAb Fc technology.
I am wondering me , too.
No news about HerpV. Why?
Verry suspect. Maybe GSK has forbidden a pIII.